IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
08 Mayo 2024 - 7:00AM
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development
company focused on developing non-viral DNA-mediated immunotherapy
and next-generation vaccines, today announced the appointment of
Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer,
effective May 13, 2024. Dr. Lindborg has served on IMUNON’s board
of directors since 2021.
Dr. Lindborg assumes the leadership of IMUNON at
a pivotal time. Topline results from the Phase 2 OVATION 2 Study
with IMUNON’s lead asset, IMNN-001 using the TheraPlas modality, in
advanced ovarian cancer are expected by mid-summer. Phase 1
proof-of-concept data from IMNN-101 using the PlaCCine modality in
seasonal COVID-19 are anticipated by year-end.
“Dr. Lindborg is uniquely qualified to take the
reins as IMUNON’s President and CEO, bringing a track record of
success in virtually every aspect of the work before the company,”
said Michael H. Tardugno, IMUNON’s executive chairman. “Her ability
to navigate global regulatory paths, having successfully delivered
products from the clinic to the market, will be valuable to IMUNON
as our pipeline advances. We have benefited significantly from her
counsel as a director, where she has played an integral role in
establishing our strategic priorities. We now look forward to
benefiting from her expertise in a new and deeper capacity,
especially as our near-term data readouts will require important
decisions with respect to advancing various programs and
assets.”
Dr. Lindborg has nearly 30 years of
pharmaceutical and biotech industry experience with a particular
focus on R&D, regulatory affairs, executive management and
strategy development. She has designed, hired and led global teams,
guiding long-term vision for growth through analytics and
stimulating innovative development platforms to increase
productivity. She joins IMUNON from BrainStorm Cell Therapeutics,
where she was Executive Vice President and Co-Chief Executive
Officer and where she remains a member of the board of directors.
At BrainStorm she was accountable for creating and executing
clinical development strategies through registration and launch and
progressed its novel cell therapy for ALS through a positive Phase
3 Special Protocol Assessment (SPA) study with the U.S. Food and
Drug Administration. She interacted frequently with investors and
analysts, represented the company in the scientific community as
well as with the media, and played an active role in discussions
with potential business partners.
Dr. Lindborg previously was Vice President &
Global Analytics and Data Sciences Head, responsible for R&D
and marketed products at Biogen. She began her biopharmaceutical
career at Eli Lilly and Company where over the course of 16 years
she assumed positions of increasing responsibility, including Head
of R&D strategy.
Commenting on her appointment, Dr. Lindborg
said, “I have enjoyed being close to the emerging science during
the development of our IL-12 therapy TheraPlas and our PlaCCine
modalities, in addition to getting to know the depth of talent in
the company. I am thrilled to assume direct managerial
responsibilities as we work to bring these important products and
technologies to patients. I am also excited by the prospect of
creating shareholder value as we determine the next steps for our
platform products.”
Dr. Lindborg received an M.A. and Ph.D. in
statistics, and a B.A. in psychology and math from Baylor
University. She has authored more than 200 presentations and 90
manuscripts that have been published in peer-reviewed journals,
including 20 first-authored. She has held numerous positions within
the International Biometric Society and American Statistical
Association and was elected Fellow in 2008.
About IMUNON
IMUNON is a clinical-stage biotechnology company
focused on advancing a portfolio of innovative treatments that
harness the body’s natural mechanisms to generate safe, effective
and durable responses across a broad array of human diseases,
constituting a differentiating approach from conventional
therapies. IMUNON is developing its non-viral DNA technology across
its modalities. The first modality, TheraPlas®, is developed for
the coding of cytokines and other therapeutic proteins in the
treatment of solid tumors where an immunological approach is deemed
promising. The second modality, PlaCCine®, is developed for the
delivery of DNA-coded viral antigens that can elicit a strong
immunological response. This technology may represent a promising
platform for the development of vaccines in infectious
diseases.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
entering a first-in-human study of its COVID-19 booster vaccine
(IMNN-101). We will continue to leverage these modalities and to
advance the technological frontier of plasmid DNA to better serve
patients with difficult-to-treat conditions. For more information
on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical fact, including, but not limited to,
statements regarding the Company’s IND application, expectations
regarding the Phase 1 clinical study of IMNN-101, including with
respect to enrollment for the study and reporting of data, the
potential efficacy and safety profile of our PlaCCine platform,
potential partnering opportunities, and the Company’s plans and
expectations with respect to its development programs more
generally, are forward-looking statements. We generally identify
forward-looking statements by using words such as “may,” “will,”
“expect,” “plan,” “anticipate,” “estimate,” “intend” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances). Readers are cautioned
that such forward-looking statements involve risks and
uncertainties including, without limitation, uncertainties relating
to unforeseen changes in the course of research and development
activities and in clinical trials; the uncertainties of and
difficulties in analyzing interim clinical data; the significant
expense, time and risk of failure of conducting clinical trials;
the need for IMUNON to evaluate its future development plans;
possible actions by customers, suppliers, competitors or regulatory
authorities; and other risks detailed from time to time in IMUNON’s
filings with the Securities and Exchange Commission. IMUNON assumes
no obligation, except to the extent required by law, to update or
supplement forward-looking statements that become untrue because of
subsequent events, new information or otherwise.
Contacts: |
|
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
609-482-2455 |
212-838-3777 |
jchurch@imunon.com |
kgolodetz@lhai.com |
# # #
Imunon (NASDAQ:IMNN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Imunon (NASDAQ:IMNN)
Gráfica de Acción Histórica
De May 2023 a May 2024